Phaseline

Companies › BioXcel Therapeutics

BioXcel Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Psychiatry; next expected readout Jul 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dexmedetomidine (BXCL501)
Adrenergic receptor alpha-2 agonist
ADRA2A, ADRA2C, ADRA2BPhase 1SchizophreniaJul 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05025605Dexmedetomidine (BXCL501)Phase 1SchizophreniaPsychiatryJul 2027

From the company's SEC filings

Cash of $13m on 2026-06-30; operating cash outflow about $36m a year; runway about 4 months at that burn, to Nov 2026

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Targets

ADRA2A (1) ADRA2C (1) ADRA2B (1)

Companies with the same targets

Guangzhou Novaken Pharm Teikoku Pharma USA Tarian Pharma Alcon Research Acer Therapeutics Santen SAS Pharmazz ARS Pharmaceuticals Terran Biosciences Australia Tecnoquimicas

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.